YDES — YD Bio Share Price
0.000.00%
Last trade - 00:00HealthcareAdventurousMicro Cap
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 1st Jan | Unit | 1966 | 1967 | 1968 | 1969 | 1970 | 1971E | 1972E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
YD Bio Limited is a biopharmaceutical company. The Company is focused on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of diseases with unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. It is focused on advancing a diversified portfolio of healthcare solutions across oncology diagnostics, regenerative medicine and clinical trial support. It is a supplier of clinical trial drugs and has expanded into the development and distribution of post-market auxiliary products. Its core programs include Blood-Based Cancer Detection, Stem Cell- and Exosome-Based Ophthalmology Therapies, and Clinical Trial and AncillaryServices. It is developing proprietary DNA methylation-based detection technology for a range of cancers, which includes a screening test for the early detection of pancreatic cancer and a monitoring test for recurrent breast cancer.
Directors
- Last Annual
- January 1st, 1970
- Last Interim
- January 1st, 1970
- Incorporated
- November 15th, 2024
- Public Since
- August 29th, 2025
- No. of Shareholders
- 10
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 70,521,359
- Address
- 12F, No. 3, Xingnan Street,, TAIPEI, 115
- Web
- http://ir.ydesgroup.com/
- Phone
- Auditors
- Marcum LLP
Upcoming Events for YDES
Breeze Holdings Acquisition Corp Annual Shareholders Meeting
Similar to YDES
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
ABPRO Holdings
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Actuate Therapeutics
NASDAQ Global Market
FAQ
What is the YD Bio share price?
As of Today at 24:13 UTC, shares in YD Bio are trading at $20.09. This share price information is delayed by 15 minutes.
How has the YD Bio share price performed this year?
Shares in YD Bio last closed at $20.09 and the price had moved by +76.9% over the past 365 days. In terms of relative price strength the YD Bio share price has outperformed the S&P500 Index by +55.68% over the past year.
What are the analyst and broker recommendations for YD Bio?
There is no consensus recommendation for this security.
Find out moreWhat is the YD Bio dividend yield?
YD Bio does not currently pay a dividend.
Does YD Bio pay a dividend?
YD Bio does not currently pay a dividend.
When does YD Bio next pay dividends?
YD Bio does not currently pay a dividend.
How do I buy YD Bio shares?
To buy shares in YD Bio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of YD Bio?
As of the previous close price of $20.09, shares in YD Bio had a market capitalisation of .
Where are YD Bio shares listed?
Here are the trading details for YD Bio:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: YDES
What kind of share is YD Bio?
Based on an overall assessment of its quality, value and momentum YD Bio is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a YD Bio share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the YD Bio share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like YD Bio. Over the past six months, its share price has outperformed the S&P500 Index by +34.06%.
As of the last closing price of $20.09, shares in YD Bio were trading +60.81% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the YD Bio PE Ratio?
The YD Bio PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $20.09.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of YD Bio?
We do not have data on YD Bio's directors